Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.
P, S., D, B., PS, L., N, H., H, S., C, U., & X, B. (2026). Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.. RMD open. https://doi.org/10.1136/rmdopen-2026-007006
P S, D B, PS L, N H, H S, C U, et al. Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.. RMD open. 2026; doi: 10.1136/rmdopen-2026-007006
P S, D B, PS L, et al. Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.[J]. RMD open. 2026. DOI: 10.1136/rmdopen-2026-007006.
@article{p2026,
author = {Sewerin P and Bismpos D and Lange PS and Horstmann N and Sprave H and Ukena C and Baraliakos X},
title = {Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.},
journal = {RMD open},
year = {2026},
doi = {10.1136/rmdopen-2026-007006},
note = {PMID: 42342287},
}
TY - JOUR AU - Sewerin P AU - Bismpos D AU - Lange PS AU - Horstmann N AU - Sprave H AU - Ukena C AU - Baraliakos X TI - Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis. T2 - RMD open PY - 2026 DO - 10.1136/rmdopen-2026-007006 AN - PMID:42342287 ER -
BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory systemic disease that is associated with cardiovascular comorbidities, particularly with an increased risk of arrhythmias. Despite the evidence, a structured population-based risk stratification that relates ECG parameters to clinical characteristics in PsA is still lacking. METHODS: Data from patients diagnosed with PsA who presented to our centre between 2014 and 2022 as well as from an age-matched and sex-matched control group of cardiovascular patients were collected. A variety of established ECG parameters associated with atrial and ventricular repolarisation and atrioventricular conduction as well as a comprehensive set of clinical variables were evaluated. RESULTS: A total of 725 patients with PsA alongside 725 matched cardiovascular patients were enrolled (mean age 52.5±13.4 years). The median duration of PsA was 2 years. Patients with PsA had similar rates of first-degree atrioventricular block (AVB I°) with the control group (9.5% vs 10.2%; p=0.725). After excluding patients with known atrial arrhythmias, patients with PsA had higher rates of significant P-wave terminal force in V1 versus controls (30.2% vs 14.1%; p<0.001). Furthermore, patients with PsA had a longer corrected Tpeak-Tend interval (0.26±0.04 vs 0.23±0.05; p<0.001). After adjusting for age, among patients with PsA, male sex (16.4% vs 7.1%; p=0.006) as well as long disease duration (18.0% vs 6.9%; p<0.001) were associated with AVB I°. CONCLUSION: Patients with PsA are at a significantly increased risk for ECG abnormalities related to both atrial and ventricular repolarisation as well as atrioventricular conduction. Non-invasive, ECG-based tools for structured risk stratification could facilitate the early detection of patients at risk.